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Abstract
Background: While the majority of seriously ill people wish to die at home, only half achieve this. The likelihood of
someone dying at home often depends on the availability of able and willing lay carers to support them.
Dying people are usually unable to take oral medication. When top-up symptom relief medication is required, a
clinician travels to the home to administer injectable medication, with attendant delays. The administration of
subcutaneous injections by lay carers, though not widespread practice in the UK, has proven key in achieving
home deaths in other countries.
Our aim is to determine if carer-administration of as-needed subcutaneous medication for four frequent
breakthrough symptoms (pain, nausea, restlessness and noisy breathing) in home-based dying patients is feasible
and acceptable in the UK.
Methods: This paper describes a randomised pilot trial across three UK sites, with an embedded qualitative study.
Dyads of adult patients/carers are eligible, where patients are in the last weeks of life and wish to die at home, and
lay carers who are willing to be trained to give subcutaneous medication. Dyads who do not meet strict risk
assessment criteria (including known history of substance abuse or carer ability to be trained to competency) will
not be approached. Carers in the intervention arm will receive a manualised training package delivered by their
local nursing team. Dyads in the control arm will receive usual care. The main outcomes of interest are feasibility,
acceptability, recruitment rates, attrition and selection of the most appropriate outcome measures. Interviews with
carers and healthcare professionals will explore attitudes to, experiences of and preferences for giving
subcutaneous medication and experience of trial processes. The study has obtained full ethical approval.
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Discussion: This study will rehearse the procedures and logistics which will be undertaken in a future definitive
randomised controlled trial and will inform the design of such a study. Findings will illuminate methodological and
ethical issues pertaining to researching last days of life care.
The study is funded by the National Institute for Health Research (Health Technology Assessment [HTA] project 15/10/37).
Trial registration: ISRCTN, ISRCTN 11211024. Registered on 27 September 2016.
Keywords: End-of-life care, Care of the dying, Palliative care, Symptom control, Carer administration,
Randomised pilot trial
Background
Introduction
Caring for the dying during their last few days of life, in
a place of their preference, is an essential part of health
and social care. The majority express a wish to die at
home (79%); however, only half of those achieve this [1].
The likelihood of patients remaining at home often de-
pends on availability of able and willing informal carers
[2–4]. These carers take on numerous care tasks, often
including the responsibility of assisting patients to have
their oral as-needed medications. Extending the role of
carers to include administering subcutaneous (SC) injec-
tions has proven to be key in achieving home death in
other countries [5].
Pain, nausea/vomiting, restlessness/agitation and noisy
breathing (rattle) are common symptoms in the dying
[6, 7]. In addition to regular (background) medication,
given via continuous SC infusion using a syringe pump,
guidelines suggest using additional (‘as -needed’) medi-
cation for symptoms that ‘break through’ [8, 9]. As dying
patients are commonly unable to take oral medication,
as-needed medication is most often given as a SC injec-
tion by a healthcare professional (HCP) [8], usually a
district nurse (DN) in the UK.
Medication for breakthrough symptoms is usually pre-
scribed in advance (anticipatory prescribing) and kept in
the patient’s home. Medication administration can be se-
verely delayed by HCPs’ travel time to the home and/or
the non-availability of anticipatory medication in the
home. Delays happen even with dedicated out-of-hours
(OOH) ‘rapid response’ nursing services for home-based
dying patients. Our local audit revealed long waits. The
median wait from call to OOH service for symptom
control to as-needed medication administration by HCP
was 86 min (mean = 99 min, range = 35–167 min), not
including time from administration to onset of action or
symptom control. Breakthrough pain is usually quick in
onset with a median duration of 30 min [10]. Long waits
mean that pain is often not adequately managed in the
home setting, as shown in the National Survey of Be-
reaved People (VOICES) [1].
This project focuses on timely administration of
as-needed medication for dying patients being cared for
at home, particularly whether lay carer role-extension
(to be trained to give as-needed SC injections) is feasible
and acceptable in the UK.
Rationale
Although carer administration of medication (including
strong opioids) is lawful and practical [11], it is not cur-
rently part of usual care everywhere in the UK. This
practice is much-needed: the national Palliative and End
of Life Care Priority Setting Partnership (PeolcPSP) sur-
veyed 1403 people including patients within the last
years of life, current and bereaved carers, and HCPs on
their unanswered questions about palliative and
end-of-life care. They accorded highest priority to re-
search into the provision of palliative care, including
symptom management, outside of working hours to
avoid crises and help patients to stay in their place of
choice. The survey noted the information and training
needs of carers and families to provide the best care for
their loved one who is dying, including training for giv-
ing medicines at home [12]. Data from the PeolcPSP in-
dicated that UK patients are being denied the
opportunity to die at home due to lack of access to ad-
equate symptom relief [13, 14].
Carers across the world embrace this as an option, as
evidenced through the published literature as well as evi-
dence from our Patient Public Involvement (PPI) group
consultations. In Australia, the practice is
well-established (> 30 years) and highly acceptable [5]. A
manualised educational package and evidence-based
guidelines are available.
Successful carer-administration of as-needed SC medi-
cation for breakthrough symptoms in a dying patient may:
▪ improve the experience (and thus increase the
likelihood of a ‘good death’) for the patient who
chooses to be at home by providing speedier symptom
control and supporting their wish to die at home;
▪ empower lay carers through the personal fulfilment of
having supported a patient’s wish to stay at home,
increase satisfaction, and reduce anxiety and frustration
related to poor symptom control;
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▪ reduce inappropriate emergency (crisis) admissions
due to uncontrolled symptoms and their associated
costs [15, 16];
▪ free up community staff time to address other needs
of patients and families, contributing to sustainability of
services.
This practice appears acceptable and has become em-
bedded in Australia. However, as per our rapid review,
there are no randomised studies testing carer-adminis-
tered non-oral medication in the last days of life for
home-based patients anywhere else in the world.
Equipoise is emerging on this topic in the UK.
Carer-administration of as-needed non-oral (including
SC) medication for breakthrough symptoms in home-
based dying patients is practised in a limited way in some
areas in the UK and has been for a number of years. For
this to be widely available to all carers who are considering
supporting a loved one at home, it must be tested in a UK
environment, with the support of an evidence-based carer
education programme and resources. Not all family, carers
or patients at home will want to be involved in this prac-
tice; the research will help to ascertain the proportion of
those who are interested and how to train and support
those who are willing.
How does the existing literature support this project?
A. Carers prioritise rapid symptom control and are will-
ing and able to administer injectable drugs, including
controlled drugs such as morphine: a narrative literature
review of family carer perspectives on supporting a dying
person at home illustrated the desire of families to pro-
vide immediate symptom relief [17]. Our review found
that caregivers are willing to learn to overcome reserva-
tions about administering SC medications. The ability to
alleviate their loved ones’ symptoms and support them
to stay at home was of paramount importance.
B. There is an existing evidence-based education pack-
age and medication resources: a Brisbane group devel-
oped and evaluated an educational package [5, 18] and a
randomised trial of who prepares the SC injections
(carer, nurse or pharmacist) was completed [11]. In
Singapore, a colour-coded pre-prepared ‘Comfort Care
Kit’ is in use [19], with oral and non-oral as-needed
medication for caregiver administration. A telephone
survey of 49 family carers showed that 67% used the
kit, all family members found it easy and 98% found
it effective for symptom management. All except one
patient died at home. In Canberra, the provision of
an Emergency Medical Kit (including for use by lay
carers) was largely viewed as an effective strategy in
giving timely symptom control and preventing in-
patient admissions [20].
C. There is growing UK evidence about the carer-role
for patients in the last months/year of life, but there are
few studies focusing on the last days of life (as reiterated
by the Neuberger Review into the Liverpool Care Path-
way) [21]. The evidence that is beginning to accumulate
mostly focuses on patients who have capacity within the
last year of life. UK/Australian research includes
‘Unpacking the home’ [22, 23]. The Cancer Carers Medi-
cation Management work [24], the SMARTE study [25]
and IMPACCT [26]. Our project, in contrast, focuses on
the last few days of life, where capacity is likely to be ab-
sent, with very different implications and issues for
carer-administration.
Community receptivity
The UK is ready for testing this extended lay carer role:
▪ primary care teams and families are used to similar
practices in other areas of medicine (insulin for
diabetes, intravenous antibiotics for children with cystic
fibrosis);
▪ the PeolcPSP report incorporated the views of 1403
people across the UK and placed great emphasis on
empowerment of family carers and symptom
management during the last days of life [12];
▪ the ‘Ambitions for Palliative and End of Life Care: a
framework for local action’ was published in Sept 2015
[27]. It was jointly developed and published by the
National Partnership for Palliative and End of Life Care
(27 national organisations) and has widespread support,
especially as the Partnership included the Patients’
Association and charities with large PPI groups. They
identified eight foundations for the six ambitions; one
of these foundations relates to ‘Involving, supporting
and caring for those important to the dying person’,
acknowledging their importance in the caring team.
Each ambition has a set of building blocks – the one on
‘practical support’ in ambition 6 is particularly
applicable to CARiAD as it calls for finding ‘new ways
to give the practical support, information and training
that enables families … to help’. There has been strong
positive reception to the framework and many localities
are using it to consider their local strategies. Its
message about shared ownership and responsibility is
particularly pertinent;
▪ in the UK, this practice is not widely accepted as
usual care. However, over the past few years, we have
identified a small number of geographically distinct
sites where the practice occurs (< 10). Recently, the
Lincolnshire project was showcased on national radio
as part of a series of talks on dying [28, 29]. Since the
conception of the CARiAD study, other areas have
expressed interest in exploring the practice, including
joining as a site of a future definitive trial.
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Pressure on health and care services in the UK
HCPs in all three sites have been universally positive to-
wards testing the intervention; if found to be beneficial,
this could make their patients more comfortable and
their jobs more manageable. In the longer term, this
innovation could relieve some pressure on Emergency
Departments by reducing inappropriate emergency (cri-
sis) admissions due to uncontrolled symptoms [15, 16].
Pressure on DN time could also be relieved as extra
visits (in addition to the daily check) to administer
as-needed medication would decrease, contributing to
sustainability of services.
Phase 1 work
Expert stakeholder workshops
To inform the development of the intervention and spe-
cific processes at each site, three expert stakeholder
workshops were conducted, one in each recruitment
site. Half-day face-to face workshops were convened,
based on the successful model used in the El-CID trial
[30]. Each workshop had 10–15 participants represent-
ing patients, carers, general practitioners (GPs), DNs,
pharmacists and specialist palliative care (SPC) clini-
cians. Two research team members facilitated, setting
the context and background to the proposed interven-
tion. Notes were kept which allowed a report of pro-
ceedings to be generated.
Participants discussed trial procedures, which were
then developed based on the consensus reached. The is-
sues covered were: Identification and risk assessment,
and approach to potential participants; Consent; Pre-
scription, supply and storage of drugs; Delivery of the
intervention; Monitoring and accountability; Outcome
measures collection; Post-bereavement interviews; and
Ethical considerations.
Trial-specific materials were also developed to reflect
the consensus reached: for HCPs – prescribing advice
(relating to patients and carer in the intervention arm),
competency checklist, risk assessment; for carers – Carer
Diary, carer information booklet ‘Subcutaneous medica-
tion for breakthrough symptoms in the last days of life: a
Guide for carers’, step-by-step guides.
Study aims
Research Question: Is carer-administration of as-needed
SC medication for breakthrough symptoms in home-
based dying patients feasible and acceptable in the UK?
P = Patients in the last days of life who are becoming
unable to take their usual oral as-needed medication
for breakthrough symptoms, being cared for at home,
and their carers
I = Carer-administration of as-needed SC medication
for common breakthrough symptoms such as pain,
restlessness/agitation, nausea/vomiting and noisy
breathing/rattle, supported by tailored education
C = Usual care (HCP-administration of as-needed SC
medication)
O = Main outcomes of interest: Feasibility and
acceptability, recruitment, attrition, contamination
We will undertake a randomised pilot trial of
carer-administered as-needed SC medication for com-
mon breakthrough symptoms in home-based dying pa-
tients versus usual care, with an embedded qualitative
component, to inform the design of a future definitive
phase 3 randomised controlled trial (RCT).
Methods/Design
Trial design and setting
The study will be a multicentre pilot RCT carried out in
community settings in Gloucestershire, North Wales
and the Vale of Glamorgan where patients are likely to
die at home in accordance with their wishes. The three
pilot study sites have been chosen as they are represen-
tative of the range of sites for a future definitive study.
The trial was funded by the Health Technology As-
sessment Programme of the National Institute for
Health Research (National Health Service). It has re-
ceived a favourable ethical opinion from the Wales 1
National Research Ethics Committee (REC reference:
17/WA/0208, IRAS project ID: 227970) and the Bangor
University Research Ethics Committee. The UK Medi-
cines and Healthcare products Regulatory Agency
(MHRA) has advised that this pilot RCT is not a Clinical
Trial of an Investigational Medicinal Product (CTIMP).
The study is registered on the International Standard
Randomised Controlled Trials Number (ISRCTN) regis-
try (ISRCTN11211024). Approval was granted from the
Research and Development departments of all three
sites. SPIRIT 2013 recommendations and CONSORT
2010 statements (including those specific to randomised
pilot and feasibility trials) guided protocol development
[31, 32]. The current version of the protocol can be
accessed via the National Institute for Health Research
(NIHR) Journals Library [33].
Inclusion/exclusion criteria for participants and recruitment
Inclusion criteria Dyads of
▪ an adult (aged ≥ 18 years) patient in the last weeks of
life, who is likely to lose the oral route for medication
and who has expressed a preference to die at home; and
▪ their adult (unpaid) lay/family carer, who is
willing to have this extended role and have
SC-injection training.
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Prognostication is reliant on the professional judge-
ment of, and agreement within, the attending HCP
team. There is an assumption that the carer will
spend a significant amount of time with the patient.
While Australian experience indicates that one lay
person generally takes a lead role in this practice,
where there is more than one suitable carer, we will
ask the patient to identify which carer they would like
to be included in the study.
Exclusion criteria Patients who have only paid/formal
care or with previously known adverse reactions to the
‘usual’ as-needed medications will be excluded. Patients
or lay carers who have not met the risk assessment cri-
teria (see below) will not be approached for consent.
Patient identification Patient / carer dyads will be
identified through the hospice, SPC service or DN team.
When a patient is perceived by the HCP team to be in
the last weeks of life and they have expressed a wish to
be cared for and die at home, they will be screened for
approach.
Screening To be eligible, dyads must satisfy the risk as-
sessment criteria. A risk assessment screening tool has
been refined for CARiAD, based on existing
self-medication tools [34]. Risk assessment is based on
clinical knowledge and judgement of the situation and
will take into account several factors, including:
▪ the carer’s mental state, vision and physical condition;
▪ the dyad’s attitudes to medicines and willingness to
engage with the healthcare team;
▪ relational issues including concerns about burden;
▪ history of substance misuse in the family.
The risk assessment will be conducted by the health-
care team involved in the patient’s care. If a dyad does
not satisfy the risk assessment criteria, they will not be
approached.
Approach The patient will be approached with written
material by a member of their healthcare team. The initial
patient approach will be done separately from the carer,
unless otherwise requested by the patient and if the at-
tending HCP deems this appropriate, i.e. there is no per-
ceived risk of patient–carer coercion. As the project
involves sites in Wales, the Participant Information Sheets
and consent forms will be translated into Welsh for the
Welsh centres and offered bilingually to comply with the
Welsh Language Act 1993. Dyads will be given as much
time as they need to consider the information sheets and
discuss with family, friends or the healthcare team until
they decide whether to take part. They will be told that
they can refuse participation without giving reasons.
Informed consent A researcher will seek advance con-
sent separately from both the patient and their lay carer at
a time judged to be suitable by the attending HCP. This
gives the patient and carer as much time as they need to
understand the nature of the research, ask questions and
make their feelings clear on trial participation [35, 36].
If the patient is unable to consent, or once they lose
capacity after they have previously given consent, the
assent of a Personal Consultee will be sought (as re-
quired by the Mental Capacity Act 2005) to the patient’s
participation in the trial [35, 36]. As the risk assessment
will exclude dyads where there are concerns about rela-
tional issues between patient and carer, the carer can act
as Personal Consultee.
If the carer does not wish to act as the Personal Con-
sultee and there is no additional family member or close
friend to take on this role, we will appoint a Nominated
Consultee (e.g. a HCP not associated with the research)
who will act for all patients in this situation in the trial.
Randomisation Once the dyad has consented and base-
line data has been completed, the dyad will be rando-
mised to one of the trial arms. Secure online
randomisation hosted by the North Wales Organisation
for Randomised Trials in Health (NWORTH) Clinical
Trials Unit will be performed by the researcher who has
obtained consent. The system will use a dynamic adap-
tive method of randomisation stratifying for recruitment
centre and diagnosis (cancer/non-cancer) [37]. Confirm-
ation of allocation will be sent only to those members of
study staff who need to be aware of the result.
Blinding CARiAD is an open trial where blinded out-
come assessment is not feasible; therefore, it is important
that outcomes are as robust as possible in light of the lack
of blinding. Outcome assessors will be experienced re-
search nurses. Data entry will be completed unblinded;
the trial statistician providing data analysis will be the only
individual blinded to randomisation allocation.
Withdrawal criteria Participants remain free to with-
draw at any time from the trial without giving reasons
and without prejudicing their further treatment. This
will be made clear to all potential participants at the
time they consent to participation and throughout their
time in the trial. Non-completion of the follow-up ques-
tionnaires will not constitute formal withdrawal from
the trial; unless the participant requests withdrawal of
their data completely, it may be used to impute values
for the analysis. The risk assessment will be reviewed at
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intervals based on HCP judgement and if the criteria are
not met the dyad will be withdrawn from the trial.
Interventions
Training of carers in the intervention arm will be sup-
ported by a manualised training package based on the
Australian package ‘Caring Safely at Home’ [5]. Lay
carers will receive training on: common symptoms that
may occur in the last days of life and how to assess if
their loved one needs medication for a particular symp-
tom; how to prepare (draw up) medication and dispose
of sharps (glass ampoules and drawing up needles); how
to administer SC medication by needle-less technique
(utilising a ‘butterfly’ SC catheter); how to assess the ef-
fect of the medication; and support available, including
primary care team as well as dedicated 24/7 SPC sup-
port. If a symptom occurs for which medication is deemed
necessary (either as expressed by the patient, if able, or as
assessed by the carer), the carer can use the training out-
lined above to administer the appropriate medication.
Medication regimens
Guidelines for anticipatory prescribing for last days of
life care are in place across the UK [38, 39]. They cover
common symptoms in the dying phase: pain; nausea
and/or vomiting; restlessness/agitation; and noisy
breathing/rattle. CARiAD recruitment sites will be ad-
vised to follow usual prescribing practice. For patients in
the intervention arm only, prescribers will be provided
with specific additional advice, including instructions
not to prescribe dose ranges/steps, and that dose
changes can only be made after a face-to-face assess-
ment (and not remotely, i.e. over the telephone).
Care pathways
The usual care arm has an unchanged care pathway for
dealing with breakthrough symptoms at home for a
dying patient, with usual palliative care and DNs admin-
istering as-needed SC medication.
‘Usual routes’ for support in each recruitment area are
different. For some areas, there is direct access to a 24/7
SPC advice line for carers in addition to support from
the patient’s primary care team within or out-of-hours.
In other areas support for the carer will be via their pri-
mary care team, while the GPs and DNs can call on ad-
vice from SPC clinicians.
In the intervention arm, carers will be trained to ad-
minister as-needed SC medication, although they will
not be obliged to do this. If the carer needs the support
of a HCP, either because they would feel more confident
having a HCP present when they administer medication
or they wish the HCP to assess and give medication,
they can obtain it via the usual routes in their area. If
the carer has reached the limit of the number of
injections which can be given in 24 h (maximum three
injections for each indication per 24 h period unless the
prescribing clinician advised a maximum of fewer than
three), they will be asked to contact a HCP as review is
indicated. Usual routes for support might include DN
team, GP, GP/DN out-of-hours, Hospice at Home team
or a hospice advice line. The use of such support will be
captured in carer diaries (see ‘Study procedures’).
HCP training requirements
In order for nurses to train carers, they will themselves
receive training on: the standardised manualised educa-
tion package (adapted from the Australian work); the
legal framework (see Additional file 1); guidelines for
medication handling and administration in a community
setting; and on trial-specific materials and processes.
Study procedures
For an overview of study assessments, see Table 1.
The main outcomes of interest will be those appropri-
ate to a pilot trial, including feasibility, acceptability, re-
cruitment rates, attrition and selection of the most
appropriate outcome measures. Outcomes will be mea-
sured for patients, their lay carers and HCPs. System bar-
riers will also be noted. These measurements will be made
at baseline, on a daily basis for symptom control and lay
carer confidence, at 6–8 weeks after bereavement and at
2–4 months for a sub-sample (carer interviews).
Recruitment measurements are: the number of eligible
patients who fulfil the inclusion criteria and are willing to
be randomised expressed as a percentage of the numbers
screened; the number who withdraw after baseline assess-
ment and randomisation; the number who complete the
various outcome measurements at baseline and at later
time points; and reasons for any non-completion.
Patient measurements are: baseline information
(including demographic information, medical history,
capacity assessment, preferred place of care in the last
days of life, current drug management) and a daily Carer
Diary during the study related to the presence and treat-
ment of breakthrough symptoms (for use in both study
arms). Data points in the diary will include: initial time
breakthrough symptom triggered perceived need for an
additional SC dose; whether noted by patient or lay
carer; medication and dose, and time given; reason for
medication (pain, nausea, restlessness, noisy breathing);
symptom score before and 30 min after medication ad-
ministration; and when symptom control/reduction of
symptom to acceptable level was achieved. Hospital or
hospice admissions during last illness and actual place of
death will also be recorded.
Carer measurements are: demographic information at
baseline; Quality of Life in Life Threatening Illness –
Family Carer Version (QOLLTI-F) (at baseline, after the
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first as-needed SC medication, then every 48 h until the
patient’s death); whether HCP support was sought; Carer
Experience Scale at baseline and after bereavement;
Family Memorial Symptom Assessment Score – General
Distress Index (MSAS-GDI) at 6-8 weeks'
post-bereavement visit; and qualitative interviews for a
sub-sample at 2–4 months after bereavement. Specific to
the intervention arm, confidence (in administering injec-
tion) and competence at intervals after training will be
recorded.
HCP measurements are: baseline measurements of at-
tending team structure; primary prescriber; carer trainer;
and evaluation of the training package.
Safety
The CARiAD project contains a number of safety out-
come measures at different stages of the clinical journey
taken by patients, carers and HCPs. Safety outcome
measures include the risk assessment, competency
checklist and Significant Event reporting. Significant
Event reporting will include the following: the appropri-
ateness of administration (is administration accompan-
ied by evidence of need?); proportionality (has the
correct dose been administered?); side effects both antic-
ipated and not anticipated; drug accountability (do
stocks tally?); and carer events (e.g. distress, needle stick
injury, accidental or purposeful self-administration).
An adverse event (AE) is defined as any untoward
medical occurrence in a trial participant (either patient
of carer) and includes incidents that are not necessarily
caused by or related to the trial. A serious adverse event
(SAE) is any untoward occurrence that results in death,
is life-threatening, requires inpatient hospitalisation or
prolongation of existing hospitalisation, results in per-
sistent or significant disability/incapacity or is otherwise
medically significant.
All AEs and SAEs will be captured via Significant
Event form. SAEs must be reported to the Principal In-
vestigator (PI) and Sponsor within 24 h. As this is a
study in patients who are terminally ill, death is an ex-
pected outcome. It will be recorded and reported to the
sponsor, but will not be considered a SAE if, in the opin-
ion of the PI, it was a natural conclusion to a patient’s
terminal illness. Due to the nature of the study, events
of death will not require immediate reporting to the
Data Monitoring and Ethics Committee (DMEC).
Exploratory endpoints/outcomes for a future definitive trial
The most likely candidates for primary outcome mea-
sures for a future definitive trial are: MSAS-GDI (a
measure of overall symptom burden/distress in the last
seven days of life) [10, 40–42] and QOLLTI-F (a meas-
ure of quality of life of carers looking after someone with
a life-threatening illness, incorporating elements of con-
trol and self-efficacy) [43].
In addition, we will measure carer confidence using a
5-point Likert scale (where the carer is asked after ad-
ministration of every as-needed SC injection to rate their
level of confidence in administering this injection, 1 =
not at all confident, 5 = very confident) and probe carer
experience during qualitative interviews.
Table 1 Overview of study assessments
Assessments Screening Baseline Last days of patient’s life After patient’s death
Eligibility X X X
Informed consent X X
Demographic information X
Medical history X
Concomitant medications X
Symptom control Symptom scores X
Overall symptom burden X
Time to symptom relief X X
Safety Risk assessment X
Competency Checklist X X
Significant Event reporting X
Evaluation of training package X
Impact on carer Self-efficacy X X X
Confidence X
Acceptability X
Health Economic outcomes Impact on carers X X
Discrete Choice Experiment attribute selection X
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Criteria for assessing feasibility as primary outcome
measure: all outcome measures will be assessed on the
same criteria (applicability, acceptability and level of
completeness) for consistency. Once the feasibility of the
outcomes is established, the design of the definitive trial
will be confirmed. The potential suitability of the follow-
ing secondary outcomes will be considered: ‘Time to
symptom relief ’ and Carer Experience Scale [44–46].
Embedded qualitative study
The aim of the embedded qualitative component is to
inform the design and assess the feasibility of a phase 3
trial of carer-administered medication. The study will
collect interview data from HCPs and carers to:
▪ assess clinical willingness to randomise patients for a
future full RCT;
▪ understand the experience of randomisation between
intervention and control, to identify relevant patient-
centred outcomes for a phase 3 trial and to consider
time points for assessment.
The qualitative study aims to include interviews with
non-consenters to the trial, as well as in-depth qualita-
tive exploration of carer and HCP acceptability of
carer-administered SC medication, e.g. strong opioids,
anti-emetics, sedatives. The study will use a phenomeno-
logical and pragmatic approach to understand the mean-
ing that carer-administration of injectable strong opioids
and other as-needed medication has for bereaved carers
and HCPs and the practicalities involved.
Sample
Face-to-face qualitative interviews across the three re-
cruitment sites will be conducted with:
▪ 6–10 carers who have experience of supporting a
patient in the intervention arm;
▪ 6–10 carers who have experience of supporting a
patient receiving usual care;
▪ 6–10 carers who declined to be randomised to the
trial. For carers in all three groups, sampling criteria
will include gender and rurality;
▪ up to 30 HCPs – to include prescribers (e.g. GPs and
ANPs), administering HCPs (e.g. DNs) and SPC
clinicians. Sampling criteria will include years since
qualification, experience of supporting home deaths
and practice characteristics.
Consent
Carers declining to take part in the trial will be
approached upon declining and invited to participate in
an interview about the reasons why they chose not to
participate. They will be given a separate information
sheet for this.
Data gathering
Interview topic coverage was informed by PPI input, the
systematic review and the expert consensus workshop.
Attitudes to and experiences of having administered
medication including emotional, ethical and practical re-
flections will be explored, as will issues relating to trial
recruitment and feasibility (supply and storage of medi-
cation, success of training and perceived competence of
carer once trained, choice and recording of the primary
outcome). Carers will be interviewed approximately 2–4
months after bereavement (as suggested by usual clinical
follow-up and current literature) [1, 47–49].
Interviews will be face-to-face at carers’ homes or al-
ternative preference, or possibly by telephone, lasting
30–60 min. The interviews with carers who declined to
be randomised to the trial will be shorter, lasting 15–20
min. HCP interviews will be by telephone and last
around 30 min. All interviews will be audio recorded,
transcribed verbatim and the carer interviews will be
managed using NVivo. Participants will be asked to con-
sent to publication of anonymised quotes.
Analysis
The analytic frameworks are selected to understand the
meaning that carer-administration of injectable strong
opioids and other as-needed medication has for bereaved
carers and HCPs. Carer interviews will be analysed using
Interpretative Phenomenological Analysis [IPA] to allow
a deeper, inductive analysis of the data in the context of
carers’ and patients’ daily lives and values [50]. This
methodology focuses on the subjective experience of
participants, as interpreted by the researcher. HCP inter-
views will be analysed using Framework Analysis with a
deductive approach [51]. Framework analysis is com-
monly used in healthcare and is more appropriate for
examining the specific aims and objectives of the HCPs.
The data will be summarised thematically and displayed
on a matrix linking to the original data.
Identification of attributes for a future Discrete Choice
Experiment (DCE)
We have identified the need to determine carers’ prefer-
ences for HCP versus own administration of medication
to patients, using a DCE. The preferences of carers to-
wards administering SC medications will have a bearing
on their willingness to adopt this practice and the effect-
iveness of carer-administered medication.
While the DCE (aiming to ascertain carers’ preferences
for their administration of SC medications) will be con-
ducted as part of a future main study, the preparatory
work required to identify relevant attributes and levels will
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be done as part of the embedded qualitative study compo-
nent of the randomised pilot study. This will be done with
each of the three carer groups in the second part of the in-
terviews and will take up to 20 min. Attributes may feas-
ibly include cost, time, perceived competency, confidence
and potential risks. The process of attribute development
will be informed by best practice [52].
The use of interviews for the determination of DCE at-
tributes enables a greater opportunity for in-depth ex-
ploration of particular issues and concepts than would
otherwise be possible in focus groups (which are more
common in DCE development). Individual interviews
are also better suited to discussions concerning sensitive
topics. Within the first five interviews in each group,
carers will be presented with a range of attributes, iden-
tified by the research team as being likely to affect
carers’ choice for own versus HCP administration of SC
medications. Interviewees will have an opportunity to
add other factors of their own choosing to the list and
be asked to identify and rank attributes in order of im-
portance. Thereafter, we will use the interviews to
pilot the presentation of the highest ranked attributes.
The ordinal ranking across each group will be deter-
mined and those ranked highest will be taken forward
for DCE development. We have successfully imple-
mented this method in previous DCEs [53] and it is
consistent with the reductiveness approach of attri-
bute development [52].
We will also pilot the Carer Experience Scale as a
means to estimate carer utility [46]. The index values de-
rived from this scale offer a preference-based approach
to incorporate the effects on carers in economic evalu-
ation, focusing on care (rather than health)-related qual-
ity of life.
Statistical considerations
Sample size
A fully justified sample size is not required; size has been
justified by estimating what a future definitive RCT will
need. Assuming an important difference of 0.4 (SD=1)
on the Family MSAS-GDI a sample of about 216 is re-
quired to achieve 90% power to detect a difference of
this size with a significance level of 0.05 using a
two-sided test. Equivalently a sample of about 550 would
be required to detect a difference of 0.5 points (SD=2)
using the QOLLTI-F.
Using the larger of these estimates for the feasibility
trial, we will assume about 9% of the main trial size, to
give an 80% confidence interval to exclude a clinically
important difference, requires ~ 25 in each group [54].
Sim and Lewis recommend a sample of about 50–55 to
ensure robust estimates of the variance [55]. Using esti-
mates of dropouts, we predict we need to approach 200
potential participants to achieve 100 randomised
participants, with 50 completers. (‘Completer’ is defined
as a dyad who completed all the study measures from
baseline to follow-up at 6–8 weeks after bereavement.)
We will therefore need to approach 5.5 dyads per month
from each of the three sites and randomise 2.7 dyads per
months from each of the three sites to meet our recruit-
ment target. Assuming we will recruit equally between the
three areas, we need to approach 66, randomise 33–34
and have 16–17 available per area for analysis (see Fig. 1:
Trial flowchart).
As per the 2013 Office of National Statistics data de-
scribed earlier, we know that 8.6% of all deaths are home
deaths due to neoplasms in those aged > 15 years [1].
Deaths due to neoplasms are seen as a useful proxy for
expected deaths. Therefore, the three recruitment areas
have the following numbers available per annum: North
Wales = 653; Gloucestershire = 517; and Vale of
Glamorgan = 349.
Statistical analysis
Primary analysis will be concentrated on the feasibility
metrics and adherence outcomes based on the thresh-
olds defined in Table 2. There will be limited preliminary
analysis of intervention outcomes. Point and 95% confi-
dence interval estimates will be calculated and used to
estimate variability and direction of effect to further in-
form the sample size calculation for a definitive study.
Summary statistics of all outcomes will be used to
inform the approximate models of analysis that would
be used in a full trial. Models will be specified once
the data is better understood through the feasibility
trial (e.g. numbers of episodes where as-needed medi-
cation used, proportion of participants that never re-
quired as-needed medication). A preliminary analysis
of the outcomes will be completed using an
intention-to-treat approach. All analysis undertaken
will be prespecified in a statistical analysis plan that
will be written and agreed before data collection is
completed.
As this is a feasibility trial, there will be no imputation
of missing data. Missing data will be considered as a cri-
terion for assessing the suitability of measures. Descrip-
tive statistics will be produced for each of the outcome
measures, to evaluate the appropriateness of the mea-
sures for inclusion in a definitive RCT.
Progression to full trial
Clear progression rules are defined to determine whether
an application for a future substantive trial powered to
study effectiveness and cost-effectiveness should proceed.
Our progression rules will relate to the following mea-
sures; which we considered important to feasibility:
Poolman et al. Trials          (2019) 20:105 Page 9 of 16
Fig. 1 Trial flowchart
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– reaching our target (16–17) for the number of
patients recruited per site.
We have also established clear assessment criteria for
establishing the acceptability of the potential primary
outcome measures.
The table below summarises the objectives, action plan
and criteria for progression to a full trial.
Governance
Trial governance procedures adhere to the NIHR guide-
lines and include a Trial Management Group (TMG), an
independent Trial Steering Committee (TSC) and an in-
dependent DMEC. SAEs will be reported to the TSC
and DMEC in line with NIHR guidance [56].
Trial Steering Committee (TSC)
The TSC nominees have been reviewed and appointed
as members by the NIHR Programme Director. The
independent members include a Chair, statistician,
primary and palliative care clinicians and two public
contributors. All TSC meetings have a minimum of
75% majority of independent members. TSC responsi-
bilities include [56]:
▪ providing advice, through its Chair, to the Trial
Funder, the Trial Sponsor, the Chief Investigators, the
Host Institution and the Contractor on all appropriate
aspects of the project;
▪ concentrating on progress of the trial, adherence to
the protocol, patient safety and the consideration of
new information of relevance to the research question;
▪ ensuring that the rights, safety and wellbeing of the
participants are the most important considerations and
should prevail over the interests of science and society;
▪ ensuring appropriate ethical and other approvals are
obtained in line with the project plan;
▪ agreeing proposals for substantial protocol
amendments and provide advice to the sponsor and
funder regarding approvals of such amendments.
Data Monitoring and Ethics Committee
The DMEC nominees have been reviewed and appointed
as members by the NIHR Programme Director. All
Table 2 Objectives, action plan and criteria for progression to a full trial
Objectives Action plan Threshold for progression to definitive RCT
1 To refine the assessment and outcome
measures to be used in any potential RCT
Qualitative feedback will be collected from
participants 2–4 months after the intervention,
regarding the acceptability of the measures and
will evaluate whether all of the intended
information was captured
2 To evaluate the acceptability of the
manualised intervention
(and potentially refine)
An initial workshop with the Australian team
was held (Nov 2015). Expert consensus
workshop discussions led to refined trial
processes, education package and resources [30]
A detailed process is described in the study
protocol clarifying the legal and regulatory
framework for the practice
In the feasibility study the simplest method is
for lay carers to draw up medications only in
immediate form; a full trial would be more
appropriate if able to extend this to advance
preparation and labelling
3 To evaluate the recruitment process Referral sites and referral sources
Where participants heard about the study
Number and speed of referrals received and time
elapsed between initial contact made with the
study team (for information and consent form)
In the feasibility we have assumed 50%
recruitment – we would say a full trial is not
possible if recruitment falls < 30%
4 To estimate participant retention rate
for the full RCT
Retention rates will inform the refinement of
the sample size calculation for any potential
subsequent RCT Participant engagement will
be monitored throughout the pilot trial
In the feasibility we have assumed 50%
retention – we would say a full trial is not
possible if retention falls < 40%
5 To test the assessment and outcome measures
for suitability, relevant change factors and
acceptability to participants
Data from the assessment process will be
compared against raw data from the outcome
measures to assess the outcome measures
sensitivity to identifying participant change
6 To identify acceptability and collection of
relevant data to inform the data collection
and analysis plan for implementation in
the subsequent RCT
A review will be completed of each outcome
measure of levels of missing data and stability to
ensure that the information collected will allow
any future main analysis to be feasible and
appropriate. Amendments can be suggested
where appropriate to amend data collection for
any potential future trial. The data available will
also inform the details for the analysis plan of any
potential full trial
Carer Diary data items successfully
completed (70%)
Family MSAS-GDI successfully completed
at bereavement visit (70%)
QOLLTI-F successfully completed at 4
8-h intervals (70%)
Poolman et al. Trials          (2019) 20:105 Page 11 of 16
members are independent and include a Chair, statisti-
cian, health economist and palliative care clinician.
DMEC responsibilities include [56]:
▪ monitoring the unblinded comparative data and make
recommendations to the TSC on whether there are any
ethical or safety reasons why the trial should not continue;
▪ considering the need for any interim analysis advising
the TSC regarding the release of data and/or information;
▪ providing, at the request of the Project Funder, a
confidential interim or futility analysis if serious
concerns are raised about the viability of the study or if
the research team are requesting significant extensions.
To conform to the Data Protection Act 2018 and the
General Data Protection Regulation (GDPR) (Regulation
[EU] 2016/679), all data will be anonymised and stored
securely. No published material will contain patient
identifying information.
Peer review This protocol has had high-quality (inde-
pendent, expert and proportionate) peer review through
the NIHR HTA funding application process. The inde-
pendent members of the TSC and DMEC will provide
an element of continuous peer review.
Bangor University is sponsoring the study, and Professor
Chris Burton (Head of School, School of Healthcare Sci-
ences, c.burton@bangor.ac.uk) is acting for and on behalf
of the Study Sponsor. Sponsor responsibilities include:
▪ taking responsibility for putting and keeping in place
arrangements to initiate, manage and fund the study;
▪ confirming that everything is ready for the research
to begin;
▪ satisfying itself that the research protocol, research
team and research environment have met the
appropriate scientific quality assurance standards;
▪ satisfying itself that the study has ethical approval
before relevant activity begins;
▪ allocating responsibilities for the management,
monitoring and reporting of the research;
▪ ensuring that appropriate arrangements are in place
to approve any modifications to the design, obtaining
any regulatory authority required, implementing such
modifications and making them known;
▪ satisfying itself that arrangements are kept in place
for good practice in conducting the study and for
monitoring and reporting, including prompt reporting
of suspected unexpected SAEs.
Quality assurance and quality control
Monitoring, audit and inspection
A Trial Monitoring Plan will be developed and agreed by
the TMG and TSC based on the trial risk assessment.
Site monitoring will be done by performing site visits (at
least once per site, with a specific focus on consent re-
cording and handling of data and site files) as well as re-
motely by exploring the trial dataset.
The sites will be expected to assist the sponsor in
monitoring the study. These may include hosting site
visits, providing information for remote monitoring or
putting procedures in place to monitor the study intern-
ally. Monitoring will be conducted across all sites and
will include a focus on enrolment rates, numbers of
withdrawals and numbers of reported AEs.
Responsibilities for monitoring will be defined and
documented in the Trial Monitoring Plan.
Data handling
Procedures are in place to protect participant confidenti-
ality before, during and after the trial.
Data collection tools and source document identification
Source data will be captured on paper at the relevant
time points. A study-specific MACRO database will be
developed to allow researchers to enter data online.
MACRO allows controlled access to the data by all cen-
tres and stores a full audit trail. The electronic data cap-
tured in the MACRO database will be stored on servers
maintained by Bangor University and will be subject to
the university IT disaster recovery procedures.
Access to data and data management
Paper data at sites will be stored in locked filing cabinets
separately from identifiable participant data. Access to the
MACRO site will be secure and password-controlled.
Access to MACRO will be defined on two different
levels—access to input (researchers at sites) and access
to full dataset—which will be limited to those core team
members involved in data and trial management.
A detailed data management plan will include the def-
inition of the data quality checks that will be performed
on the data throughout the life course of the trial. These
will include source data validation, random data checks
and timelines for data entry.
Access to the final trial dataset
The trial statisticians will have full access to the dataset.
The Chief Investigators (CIs) and trial manager will have
access to the full dataset after the analysis has been com-
pleted. The DMEC will have access to the full dataset as
required. The TSC will have access to the full dataset be-
fore the individual sites having access.
Data sharing
During the course of the trial, datasets may be requested
from the trial team. A data request form will form part
of the data management plan and will document the
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approval and retrieval process for datasets during the
conduct of the trial. All requests will have to be ap-
proved by the CIs. All data requests and datasets issued
will be retained for completeness.
Data archiving
Archiving of trial documents will be authorised by the
Sponsor following submission of the end of study report.
As per the sponsor’s research data management policy, re-
search data and records will be retained ‘for as long as
they are of continuing value to the researcher and the
wider research community, and as long as specified by re-
search funder, patent law, legislative and other regulatory
requirements. The minimum institutional retention period
for research data and records is five (5) years after publica-
tion or public release of the work of the research, unless
required by the funder to retain for longer’ [57].
In line with legal requirements, trial documents will be
archived centrally at a secure facility with appropriate
environmental controls and adequate protection from
fire, flood and unauthorised access. Archived material
will be stored in tamper-proof archive boxes that are
clearly labelled. Electronic archiving will be provided by
the sponsor for post-project deposit and retention of
data. Destruction of essential documents will require au-
thorisation from the Sponsor.
Publication policy
Dissemination plan
The results of the study will be first reported to trial col-
laborators. The main report will be drafted and agreed
by the trial coordinating team and the final version will
be agreed by the HTA before submission for publication,
on behalf of the collaboration.
The study findings will be disseminated through publi-
cation in highly cited and open-access peer-reviewed
journals and submissions to national and international
conferences. In addition, dissemination of our work to
clinical and academic colleagues will be via professional
societies, newsletters, existing networks and professional
websites. Relevant NHS organisations and healthcare
providers, e.g. Clinical Commissioning Groups and Na-
tional Institute for Health and Care Excellence (NICE),
will be informed of the study outcomes.
All carer participants, if they so wish, will be sent an
accessible summary of the findings from the study
within six months of study completion. The same sum-
mary will be made available to public/patient forums to
inform patient groups across the area.
It is expected that the TMG will ensure a high level of
awareness of our work in the relevant media while ex-
ploring the use of social media to disseminate outcomes,
encourage public/patient involvement and promote fu-
ture research to improve patient care at the end of life.
Authorship eligibility
Authorship (individually named or group) on the final
trial report and manuscripts submitted for publication
will be in accordance with the authorship criteria de-
fined by the International Committee of Medical Journal
Editors [58].
Indemnity
Bangor University has appropriate Clinical Trials Indemnity
and Professional Indemnity insurance in place that will
cover members of the research team to conduct the research
as per protocol. Health and Care Research Wales staff has
NHS contracts and will be responsible to ensure that their
work is appropriately insured. NHS staff working with pa-
tients involved in the intervention will not be expected to
do anything that is not covered by their contracts and will
remain covered by the NHS insurance arrangements.
Discussion
Empowering lay carers to support a loved one’s wish to
die at home is an important part of care in the last days
of life. Role extension for lay carers allowing them the
option to give SC PRN injections is already practised
and valued in other countries. It is important and timely
to study this in the UK setting. In order to design a de-
finitive study of the clinical and cost-effectiveness of
carer administration in this context, rehearsal of the
study procedures and logistics is required. The study we
describe will fulfil this aim and will provide an exemplar
for conducting RCTs in the last days of life by contribut-
ing to the emerging methodological development of pal-
liative care research.
Specific design considerations resulted in the decision
to propose a stand-alone (external) randomised pilot
trial. These include:
▪ the current UK context (post-Shipman, post-Liverpool
Care of the Dying Pathway and with the ongoing euthan-
asia public debate), calling for careful attention to its im-
pact on consent mechanisms and attitudes of carers,
patients and HCPs to this innovation;
▪ the lack of clear UK-wide guidance on carer-
administration of as-needed SC medication to dying
home-based patients: though the practice is lawful,
current guidance is not detailed nor specific enough for
wide adoption;
▪ the lack of a clear and widely accepted training
package for lay carers, adapted for the UK context;
▪ the uncertainty about the primary outcome measure
for a definitive trial.
These are unpredictable barriers until the re-worked
Australian manualised intervention is introduced and
trial processes are tested. If the intervention is proven
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feasible and acceptable, we anticipate a phase of ensur-
ing new guidance is developed and put in place at na-
tional level in UK health systems to enable the practice
before rolling out a full trial quickly. We have demon-
strated a clear path towards a definitive RCT as per the
Medical Research Council Framework for the evalu-
ation of complex interventions principles, further in-
formed by the Methods of Researching End of Life
Care guidance [59–61].
The CARiAD team is aware of the sensitivities sur-
rounding, and ethical and methodological challenges
associated with, researching last days of life care.
With this in mind, study processes were carefully de-
veloped with strong public contribution.
Public contribution
Our team is committed to meaningful involvement of
patient representatives. Two service users are
co-applicants. Insights gained from their experiences
of giving injections to dying loved ones at home were
crucial in designing the project and they have offered
to be involved at all stages of its development. Their
involvement will be fundamental in disseminating the
research results to patients, carers and healthcare pro-
fessionals. Two additional groups of bereaved carers
have been consulted and their suggestions on consent
mechanisms, drug safety, training and ongoing sup-
port have been incorporated into the study design.
The recruitment of representatives with appropriate
and explicit experience ensures that we fully under-
stand the needs of our research participants.
This work builds on previous published work in PPI
for trials and academic units [62, 63]. In line with the
standards, the PPI representatives will be invited to
join the Involving People network in order to benefit
from its training portfolio and support systems. All
usual arrangements, refreshments, travel, access and
carer support will be in place for considerate inclu-
sion of PPI representatives at meetings. The project
will work to the NIHR’s newly developed National
Standards for Public Involvement in Research and an
audit of the standards will be reported at the close of
the study [64].
Trial status
This manuscript is a summary of the current,
HTA-agreed protocol (Version 5 [17 August 2018]), with
regard for NIHR dissemination guidance.
The study opened to recruitment in North Wales on
10 January 2018, on 1 April 2018 in Gloucestershire and
on 21 March 2018 in Cardiff & Vale. Recruitment is
aimed to be completed by the end of March 2019.
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